{"page":"/blog/pharma-programmatic-advertising","modified":"2026-11-10","license":"https://creativecommons.org/licenses/by/4.0/","columns":["Date","Company and product","Medium","FDA's finding, in brief","Letter"],"rows":[["9 September 2025","AbbVie, Skyrizi","Webpage on a health care provider branded website","Head-to-head superiority claims against Stelara found false or misleading","FDA"],["26 February 2026","Novo Nordisk, Ozempic","Direct-to-consumer video","Claims and presentations \"misrepresent the efficacy\" of the drug","FDA"],["28 April 2026","Bayer, Nubeqa","Direct-to-consumer YouTube video and Spanish-language TV ad","Benefit claims while omitting material risk information from the patient labeling","FDA"],["24 June 2026","Lundbeck, Vyepti","Two webpages on a health care provider website","Efficacy claims drawn from open-label and post-hoc analyses whose limits \"preclude\" such conclusions","FDA"],["28 September 2026","Evolus, Jeuveau","Instagram post on two company accounts, also reported through FDA's Bad Ad Program","Misleading impression of safety and effectiveness; cites 21 CFR 202.1(e)(5) and (e)(7)(viii)","FDA"]],"sourceUrls":[["https://www.fda.gov/media/188908/download"],["https://www.fda.gov/media/191387/download"],["https://www.fda.gov/media/192241/download"],["https://www.fda.gov/media/193472/download"],["https://www.fda.gov/media/195157/download"]]}